<DOC>
	<DOCNO>NCT01606982</DOCNO>
	<brief_summary>The purpose treatment protocol provide expand access MDV3100 monitor safety patient metastatic castration-resistant prostate cancer previously treat docetaxel-based chemotherapy .</brief_summary>
	<brief_title>Provide Expanded Access MDV3100 Monitor Its Safety Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy</brief_title>
	<detailed_description>THE UNITED STATES FOOD AND DRUG ADMINISTRATION ( FDA ) AND HEALTH CANADA HAVE APPROVED MDV3100 ( ENZALUTAMIDE ) FOR SALE TO THE PUBLIC , ENROLLMENT IS CLOSED IN BOTH THE UNITED STATES AND CANADA . The expanded access treatment protocol conduct marketing approval enzalutamide seek . There age requirement . Subjects complete visit Day 1 , Week 4 , Week 12 every subsequent 12 week discontinue study . The study end enzalutamide approve sale public country 's health authority ( commercially available ) sponsor otherwise decide required end study . If subject would like receive enzalutamide study end , doctor decide receive prescription enzalutamide , goal avoid interruption treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Ongoing androgen deprivation therapy gonadotropinreleasing hormone ( GnRH ) analogue ( agonist antagonist ) orchiectomy At least one prior chemotherapy regimen metastatic castrationresistant prostate cancer least one regimen contain docetaxel Progressive disease evidence prostate specific antigen ( PSA ) rise radiographic clinical worsen disease No known suspect brain metastasis There comparable satisfactory alternative therapy treat subject 's disease Eastern Cooperative Oncology Group ( ECOG ) performance status 02 History seizure condition may predispose seizure include , limited underlie brain injury , stroke , primary brain tumor , brain metastasis , alcoholism History loss consciousness transient ischemic attack within last 12 month Clinically significant cardiovascular disease Following lab value : Absolute neutrophil count &lt; 1,000/µL Platelet count &lt; 50,000/µL Hemoglobin &lt; 5.6 mmol/L ( 9 g/dL ) Total bilirubin ≥1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≥2.5 x ULN Creatinine clearance le 30 ml/min Cockcroft Gault formula Subject 's condition suggest bone fracture complication bone fracture ( compression spinal cord nerve ) likely occur soon Subject participate previous clinical study MDV3100 primary endpoint yet report ( e.g. , PREVAIL trial )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate</keyword>
	<keyword>MDV3100</keyword>
	<keyword>cancer</keyword>
</DOC>